ANEMOCYTE announces "EXELLULA"

9 Aug 2019

The new Italian industrial complex entirely dedicated to the development and production of cell and gene therapies is called EXELLULA and it will be a world centre of excellence for nonviral technologies.

EXELLULA represents one of the most significant private investments in the sector of contract manufacturing of cell and gene therapies currently underway in Europe, with over 2000 square metres of GMP and GMP-compliant facilities for the development and production of Advanced Therapy Medicinal Products (ATMP) and over 500 square metres dedicated to their research and innovation.

ANEMOCYTE announces EXELLULA

Read More